Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea BiotecBOM:531349 +0.09%54 Gross Margin % is 54.19% as of Mar. 2026, which is 9% below its 10-year median of 59.58. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹359.92 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Panacea Biotec ranks worse than 55.05% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Panacea Biotec had a gross margin of 54.19% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Panacea Biotec Gross Margin % Related Terms
Panacea Biotec Gross Margin % Historical Data
* Premium members only.
The historical data trend for Panacea Biotec's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531349 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Panacea Biotec's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Biotec Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panacea Biotec's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Panacea Biotec's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Panacea Biotec (BOM:531349) has a Gross Margin % of 54.19% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Panacea Biotec and its competitors. This is near median its historical median of 59.58. Over the past decade, Panacea Biotec's Gross Margin % has ranged from 38.99 to 67.50. According to the industry distribution chart, Panacea Biotec ranks #403 out of 732 companies in the Biotechnology industry, placing it in the top 55.1%.
Is Panacea Biotec's Gross Margin % too high?
Panacea Biotec's current Gross Margin % of 54.19% is near median its 10-year median of 59.58. Over the past 10 years, this metric has ranged from a low of 38.99 to a high of 67.50. The Biotechnology industry median Gross Margin % is 60.91. Panacea Biotec's value of 54.19% is 11% below this industry median. Based on the distribution chart, Panacea Biotec ranks #403 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panacea Biotec ranks #403 out of 732 companies for Gross Margin %. This places Panacea Biotec in the lower half of its industry. The industry median Gross Margin % is 60.91. Panacea Biotec's value of 54.19% is 11% below this benchmark. Historically, Panacea Biotec's own Gross Margin % has ranged from 38.99 to 67.50 over the past decade. While the company's 10-year median is 59.58 vs. the industry median of 60.91, Panacea Biotec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Biotec's current Gross Margin % of 54.19% is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Panacea Biotec and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Biotec's current Gross Margin % is 54.19%, which is near median its own 10-year median of 59.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹538.20 — trading 49.5% above its estimated fair value. The current Gross Margin % is 54.19%, which is near median its 10-year median of 59.58 and 11% below the Biotechnology industry median of 60.91. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Gross Margin % is 54.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panacea Biotec (BOM:531349) Overvalued in 2026?
Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued.
The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92.
GuruFocus considers Panacea Biotec to be Significantly Overvalued.
Key valuation signals for BOM:531349:
Gross Margin %: 54.19% (near median its 10-year median of 59.58)
GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
Industry Position: 11% below the Biotechnology median (#403 of 732)
No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score
Get the complete analysis for BOM:531349
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531349 has been successfully added to your 
